Martin Treder
Oprichter bij LTZ Therapeutics, Inc.
Profiel
Martin Treder founded U3 Pharma AG in 2001 and CT Atlantic Ltd.
in 2008, where he held the title of Research Director and Chief Scientific Officer, respectively.
Dr. Treder is also the founder of LTZ Therapeutics, Inc. He served as the Chief Scientific Officer at Affimed NV from 2015 to 2019.
Dr. Treder received his undergraduate degree from Monash University and his doctorate from Technische Universität München.
Actieve functies van Martin Treder
| Bedrijven | Functie | Begin |
|---|---|---|
LTZ Therapeutics, Inc.
 LTZ Therapeutics, Inc. BiotechnologyHealth Technology LTZ Therapeutics, Inc. is an American immunotherapy-focused biotech company that develops novel therapies. The company was founded by Jianhui Zhou, Robert Li, and Martin Treder, with Robert Li serving as the CEO since incorporation. | Oprichter | - |
Eerdere bekende functies van Martin Treder
| Bedrijven | Functie | Einde |
|---|---|---|
| AFFIMED N.V. | Hoofd Techniek/Wetenschap/O&O | 22-05-2019 |
CT Atlantic Ltd.
 CT Atlantic Ltd. Miscellaneous Commercial ServicesCommercial Services CT Atlantic AG focuses on the identification and development of human-derived monoclonal antibodies as novel therapeutics for the treatment of cancer. The company was founded by Alexander Knuth, Christoph Esslinger and Edward Stuart in 2008 and is headquartered in Schlieren, Switzerland. | Oprichter | 01-12-2014 |
U3 Pharma AG
 U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | Oprichter | 01-10-2008 |
Opleiding van Martin Treder
| Monash University | Undergraduate Degree |
| Technische Universität München | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| AFFIMED N.V. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
U3 Pharma AG
U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | Commercial Services |
CT Atlantic Ltd.
CT Atlantic Ltd. Miscellaneous Commercial ServicesCommercial Services CT Atlantic AG focuses on the identification and development of human-derived monoclonal antibodies as novel therapeutics for the treatment of cancer. The company was founded by Alexander Knuth, Christoph Esslinger and Edward Stuart in 2008 and is headquartered in Schlieren, Switzerland. | Commercial Services |
LTZ Therapeutics, Inc.
LTZ Therapeutics, Inc. BiotechnologyHealth Technology LTZ Therapeutics, Inc. is an American immunotherapy-focused biotech company that develops novel therapies. The company was founded by Jianhui Zhou, Robert Li, and Martin Treder, with Robert Li serving as the CEO since incorporation. | Health Technology |